Abstract 41P
Background
Radiation therapy (RT) for breast cancer (BC) can result in cardiotoxicity including subtle cardiac dysfunction that can occur early after treatment. In 2022, the first European Society of Cardiology (ESC) guidelines in cardio-oncology defined asymptomatic cancer therapy-related cardiac dysfunction (CTRCD), combining both information on left ventricle ejection fraction (LVEF) and global longitudinal strain (GLS) decrease from baseline. This newly defined event has never been studied in a population of BC patients treated with RT. Objective: To evaluate early to mid-term asymptomatic CTRCD occurrence and to analyze the association with radiation-induced cardiac exposure.
Methods
The BACCARAT study included BC patients treated with RT without chemotherapy, aged 40–75 years. Conventional and 2D Speckle tracking echocardiography was performed before RT and 6 and 24 months after RT. Whole heart, left ventricle (LV), coronary arteries doses, and dose-volume parameters were considered to evaluate the impact of cardiac exposure on CTRCD. Classic cardiac risk factors data were also collected.
Results
The study included 72 BC (of 59 left-sided BC) patients with a mean age of 58 years. A total of 32 (44%) patients developed any grade CTRCD during follow up: 22 (31%) developed early, and 14 (19%) developed midterm dysfunction with or without previous dysfunction only in left BC patients. The doses were generally higher among patients with CTRCD rather than non-CTRCD. Significant dose-response relationships were observed between the risk of CTRCD and cardiac exposure, in particular LV (OR for V2 LV dose =1.03 (1.00-1.06) p=0.01 and circumflex CX artery’s mean dose OR = 2.44 (1.26-4.74) p =0.008, D2 OR = 1.79 (1.13-2.85) p=0.01 and V2 OR = 1.02 (1.01-1.04) p=0.01. The results for the CX artery exposure were robust and significant after adjustment for classic cardiac risk factors and analyses according to the CTRCD grade; however, it did not remain significant for LV.
Conclusions
Our study suggests an association between specific cardiac structures and CTRCD, considering classic cardiac risk factors. However, given the limited number of patients, further research is needed.
Clinical trial identification
NCT02605512.
Editorial acknowledgement
Legal entity responsible for the study
Institut de radioprotection et de sûreté nucléaire (IRSN).
Funding
Société française de cardiologie Électricité de France Société française de cardiologie.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - Multivariate analysis of functional organoid assays predicts patient responses in the clinic for colorectal and pancreatic cancer
Presenter: Anna-Rose Gryspeert
Session: Poster session 07
11P - Therapeutic effects of MRTX1133 in KRAS G12D mutant appendiceal cancer: Insights from organoid and in vivo studies
Presenter: John Paul Shen
Session: Poster session 07
12P - STING-activable pyroptotic nanoparticles deliver GSDMDNT mRNA for in situ pancreatic cancer vaccination and immunotherapy
Presenter: Shiyi Shao
Session: Poster session 07
Resources:
Abstract
14P - EED inhibition renders vulnerability to immunotherapy by rewiring ceramide metabolism in pancreatic cancer
Presenter: Fan Chen
Session: Poster session 07
15P - TIGIT+ CD8+ T cells limit the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer via NECTIN2-TIGIT interplay
Presenter: Zhehui Zhu
Session: Poster session 07
16P - PTEN deficiency leads to colorectal cancer immune evasion via atypical Keap1/Nrf2 pathway
Presenter: RunKai Cai
Session: Poster session 07
17P - Breaking chemotherapy resistance in gastric adenocarcinoma: Immunogenic cell death induction by carbonic anhydrase IX targeting
Presenter: Elena Andreucci
Session: Poster session 07
18P - The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
Presenter: Silvana Lobo
Session: Poster session 07
19P - KSR1 as a therapeutic target for hepatocellular carcinoma with activated RAS-RAF-MEK-ERK signaling pathway
Presenter: HYUK MOON
Session: Poster session 07
20P - Preclinical characterization of FGFR1-4 variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 07